EyePoint announces Phase 3 plans for DURAVYU in wet AMD; positive Phase 2 data

EyePoint, Inc.

Phase 3 LUGANO and LUCIA trials to enroll ~400 patients each; 2.7mg DURAVYU vs aflibercept; one-year endpoint.
Phase 2 DAVIO 2 data: favorable safety, BCVA nearly identical to aflibercept at 12 months post single injection.
After single DURAVYU dose, ~50% of eyes were supplement-free at 12 months vs 22% for aflibercept control.
Phase 2 VERONA trial in DME fully enrolled with 27 patients; no drug-related SAEs reported.
First patient dosing in Phase 3 LUGANO expected 2H 2024; FDA alignment on non-inferiority design with redosing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.